CompletedNCT06507605Updated Feb 10, 2026

Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults

A Phase 1 interventional study of R21 and Pfs230D1-CRM197 in Prevention of Malaria Transmission and Clinical Malaria, sponsored by Serum Institute of India Pvt. Ltd.. Completed at 1 site in Mali. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Serum Institute of India Pvt. Ltd. · Phase 1, Interventional, and Prevention

Phase: Phase 1
Study type: Interventional
Enrollment: 240
Allocation: Randomized
Ages: 18 Years to 50 Years
Sex: All

Study summary

This is a Phase 1, individually randomized, double-blind, dose escalating study designed to evaluate the safety, tolerability, and immunogenicity of Pfs230D1 conjugate vaccines, R21 nanoparticle vaccine, or their combination conjugate vaccines, formulated on Matrix-M in healthy African adults aged 18 to 50 years.

Read the detailed description

240 healthy adults (18-50 years of age) will be enrolled from Mali, Africa in a staggered manner by increasing Pfs230D1 dosing.

Participants will be randomized by cohorts as (detailed below) to one of the study arms to receive single antigen (Pfs230D1 or R21) or combination (Pfs230D1 + R21) with 50 μg of Matrix-M, all administered as an IM injection on a 1, 29, 57-day schedule. Participants will be followed for safety for 6 months post last dose with continued assessment for clinical malaria cases and immunogenicity up until 12 months post last dose.

Cohort 1 (n=120); 1:1:1:1:1:1

Arm 1a (n=20): 6μg Pfs230D1-CRM197 + 5μg of R21 in 50μg Matrix-M
Arm 1b (n=20): 6μg Pfs230D1-CRM197 + 10μg of R21 in 50μg Matrix-M
Arm 1c (n=20): 12μg Pfs230D1-CRM197 + 5μg of R21 in 50μg Matrix-M
Arm 1d (n=20): 12μg Pfs230D1-CRM197 + 10μg of R21 in 50μg Matrix-M
Arm 1e (n=20): 5μg of R21 in 50μg Matrix-M
Arm 1f (n=20): 10μg of R21 in 50μg Matrix-M

Followed by Cohort 2 (n=80); 1:1:1:1

Arm 2a (n=20): 20μg Pfs230D1-CRM197 + 5μg of R21 in 50μg Matrix-M
Arm 2b (n=20): 20μg Pfs230D1-CRM197 + 10μg of R21 in 50μg Matrix-M
Arm 2c (n=20): 20μg Pfs230D1-CRM197 in 50μg Matrix-M
Arm 2d (n=20): 20μg Pfs230D1-EPA + 5μg of R21 in 50μg Matrix-M

Followed by Cohort 3 (n=40); 1:1

Arm 3a (n=20): 40μg Pfs230D1-CRM197 + 5μg of R21 in 50μg Matrix-M
Arm 3b (n=20): 40μg Pfs230D1-CRM197 + 10μg of R21 in 50μg Matrix-M

Conditions studied

Prevention of Malaria Transmission and Clinical Malaria

Who can participate

Ages eligible: 18 Years to 50 Years
Sexes eligible: All
Accepts healthy volunteers: Yes

Inclusion criteria

Age: 18 to 50 years old.
Provides written informed consent.
Able to understand and comply with planned study procedures and be available for the duration of the trial.
In good general health and without clinically significant medical history in the opinion of the investigator.
Females of childbearing potential must be willing to use reliable contraception from 21 days prior to Study Day 1 and until 1 month after the last vaccination.

Exclusion criteria

Exclusion Criteria:

Pregnant and breastfeeding females.
Hemoglobin, white blood cell (WBC), absolute neutrophil count, or platelet levels outside the local laboratory-defined reference ranges.
Alanine transaminase (ALT) or creatinine (Cr) level above the local laboratory-defined upper limit of reference range.
Infected with HIV, hepatitis B, hepatitis C.
Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies.
Current or planned participation in an investigational product study until the time period of the last required study visit under this protocol.
Medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.
History of a severe allergic reaction or anaphylaxis.
Known: Severe asthma, Autoimmune or antibody-mediated disease, Immunodeficiency, Seizure disorder, Asplenia or functional asplenia, Use of chronic oral or intravenous corticosteroids (excluding topical or nasal), Sickle cell disease.
Any other condition that in the opinion of the investigator might jeopardize the safety or rights of a subject participating in the trial, interfere with the evaluation of the study objectives, or might render the subject unable to comply with the protocol.

Study design

Phase: Phase 1
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment: 240 participants (actual)

Study arms

Experimental
Arm 1a (n=20)
6μg Pfs230D1-CRM197 + 5μg of R21 in 50μg Matrix-M
Biological: R21 · Biological: Pfs230D1-CRM197 · Other: Matrix-M
Experimental
Arm 1b (n=20)
6μg Pfs230D1-CRM197 + 10μg of R21 in 50μg Matrix-M
Biological: R21 · Biological: Pfs230D1-CRM197 · Other: Matrix-M
Experimental
Arm 1c (n=20)
12μg Pfs230D1-CRM197 + 5μg of R21 in 50μg Matrix-M
Biological: R21 · Biological: Pfs230D1-CRM197 · Other: Matrix-M
Experimental
Arm 1d (n=20)
12μg Pfs230D1-CRM197 + 10μg of R21 in 50μg Matrix-M
Biological: R21 · Biological: Pfs230D1-CRM197 · Other: Matrix-M
Active comparator
Arm 1e (n=20)
5μg of R21 in 50μg Matrix-M
Biological: R21 · Other: Matrix-M
Active comparator
Arm 1f (n=20)
10μg of R21 in 50μg Matrix-M
Biological: R21 · Other: Matrix-M
Experimental
Arm 2a (n=20)
20μg Pfs230D1-CRM197 + 5μg of R21 in 50μg Matrix-M
Biological: R21 · Biological: Pfs230D1-CRM197 · Other: Matrix-M
Experimental
Arm 2b (n=20)
20μg Pfs230D1-CRM197 + 10μg of R21 in 50μg Matrix-M
Biological: R21 · Biological: Pfs230D1-CRM197 · Other: Matrix-M
Experimental
Arm 2c (n=20)
20μg Pfs230D1-CRM197 in 50μg Matrix-M
Biological: Pfs230D1-CRM197 · Other: Matrix-M
Experimental
Arm 2d (n=20)
20μg Pfs230D1-EPA + 5μg of R21 in 50μg Matrix-M
Biological: R21 · Biological: Pfs230D1-EPA · Other: Matrix-M
Experimental
Arm 3a (n=20)
40μg Pfs230D1-CRM197 + 5μg of R21 in 50μg Matrix-M
Biological: R21 · Biological: Pfs230D1-CRM197 · Other: Matrix-M
Experimental
Arm 3b (n=20)
40μg Pfs230D1-CRM197 + 10μg of R21 in 50μg Matrix-M
Biological: R21 · Biological: Pfs230D1-CRM197 · Other: Matrix-M

Interventions

BiologicalR21
R21 is a portion of Pf circumsporozoite protein fused with hepatitis B surface antigen in the form of non-infectious virus-like particles (VLPs) produced in yeast cells (Hansenula) by recombinant DNA technology.
BiologicalPfs230D1-CRM197
Recombinant Pfs230 domain 1 (Pfs230D1; a subdomain of a surface antigen of gametocytes, gametes, and zygotes, in the mosquito stage of Pf conjugated to CRM197 and adjuvanted with 50μg of Matrix-M.
BiologicalPfs230D1-EPA
Recombinant Pfs230D1 conjugated to a recombinant Pseudomonas aeruginosa ExoProtein A (EPA)
OtherMatrix-M
Vaccine adjuvant that contains purified saponin (from Quillaja saponaria Molina) and cholesterol and phosphatidyl choline. Matrix-M will be used at a 50μg dose for vaccinations.

What researchers measure

Primary outcomes

Number of Participants with Immediate adverse events
Occurrence of immediate adverse events
Time frame: within 30-minutes following each dose
Number of Participants with Solicited local adverse events
Occurrence of solicited local adverse events
Time frame: for 7 days following each dose
Number of Participants with Solicited systemic adverse events
Occurrence of solicited systemic adverse events
Time frame: for 7 days following each dose
Number of Participants with Unsolicited adverse events
Occurrence of all unsolicited adverse events
Time frame: for 28 days following each dose
Number of Participants with Abnormal Laboratory Values post-vaccination
Any significant change from baseline for laboratory values defined as adverse events
Time frame: within 7 days following each dose
Number of Participants with Serious adverse events
Occurrence of serious adverse events
Time frame: Till 6 months post last dose

Secondary outcomes

Anti-NANP IgG antibodies
Comparison of anti-NANP IgG antibodies
Time frame: at 2 weeks post dose 3 in all treatment arms
Anti-Pfs230D1 IgG antibodies
Comparison of Anti-Pfs230D1 IgG antibodies
Time frame: at 2 weeks post dose 3 in all treatment arms

Study locations

1 site

University of Science, Technique and Technology of Bamako (Usttb)
Bamako, Mali

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

Registry details

Key details

Study ID: NCT06507605
Lead sponsor: Serum Institute of India Pvt. Ltd.
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Responsible party: Sponsor
First posted: Jul 18, 2024
Start date: Aug 30, 2024
Primary completion: Jan 24, 2026
Completion: Jan 24, 2026
Last update: Feb 10, 2026

Oversight

Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Serum Institute of India Pvt. Ltd.

Start the discussion